Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib for chronic graft-versus-host disease with skin involvement
IRCT20241027063516N1Phase 2Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Oct 2024
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of baricitinib in chronic graft-versus-host disease (cGVHD), sponsored by Tehran University of Medical Sciences. Primary endpoints: Skin sonography, Erythema and 6 more. Started Oct 2024; status: completed.
02
Drugs
baricitinib
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on IRCT20241027063516N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20241027063516N1.